Display options
Cite
Sahadevan A, Lane SJ. Palliative Subcutaneous Terbutaline Infusion in Severe Asthma. Ir Med J. 2016;109(5):410
Sahadevan, A., & Lane, S. J. (2016). Palliative Subcutaneous Terbutaline Infusion in Severe Asthma. Irish medical journal, 109(5), 410.
Sahadevan, A, and Lane, S J. "Palliative Subcutaneous Terbutaline Infusion in Severe Asthma." Irish medical journal vol. 109,5 (2016): 410.
Sahadevan A, Lane SJ. Palliative Subcutaneous Terbutaline Infusion in Severe Asthma. Ir Med J. 2016 May 10;109(5):410. PMID: 27685881.
Copy Download .nbib Format: NLM
Share it on

Ir Med J. 2016 May 10;109(5):410.

Palliative Subcutaneous Terbutaline Infusion in Severe Asthma.

Irish medical journal

A Sahadevan, S J Lane

Affiliations

  1. Department of Respiratory Medicine, AMNCH, Tallaght, Dublin 24.

PMID: 27685881

Abstract

Continuous subcutaneous infusion of terbutaline (CSIT) has been shown to improve asthma control. As an adjunct to standard asthma pharmacotherapy, 3-12mg/day of CSIT can stabilise asthmatic symptoms, reduce hospitalisations and reduce corticosteroid need1,2. Asthmatics who demonstrate a wide diurnal variability in their peak-flows (>40%), termed brittle asthmatics tend to benefit the most from this therapy3. CSIT can have adverse effects and should only be used in specialist respiratory centres.

Publication Types